Wed, September 13, 2023
Tue, September 12, 2023
Mon, September 11, 2023
Fri, September 8, 2023
Thu, September 7, 2023
Wed, September 6, 2023

Raghuram Selvaraju Reiterated (BTAI) at Strong Buy and Held Target at $11 on, Sep 8th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. g-buy-and-held-target-at-11-on-sep-8th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Raghuram Selvaraju of HC Wainwright & Co., Reiterated "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy and Held Target at $11 on, Sep 8th, 2023.

Raghuram has made no other calls on BTAI in the last 4 months.



There are 5 other peers that have a rating on BTAI. Out of the 5 peers that are also analyzing BTAI, 3 agree with Raghuram's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Graig Suvannavejh of "Mizuho" Reiterated at Hold and Held Target at $4 on, Wednesday, August 23rd, 2023
  • Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Decreased Target to $4 on, Tuesday, August 15th, 2023
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold on, Monday, July 17th, 2023


These are the ratings of the 2 analyists that currently disagree with Raghuram


  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $31 on, Tuesday, August 15th, 2023
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $20 on, Tuesday, August 15th, 2023

Publication Contributing Sources